• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Therapeutic Strategies in Lipid Disorders - Product Image

Therapeutic Strategies in Lipid Disorders

  • Published: April 2009
  • Region: World
  • 296 Pages
  • Clinical Publishing

Lipid disorders are now recognised as a diverse group of diseases that together represent one of the foremost risk factors for cardiovascular disease in general. Frequently present in association with other chronic illnesses such as hypertension, diabetes, and obesity, lipid disorders are a key therapeutic target for clinicians. This book examines the causes and consequences of lipid disorders, and the treatments available. Special chapters are dedicated to the associations between lipid disorders and other conditions, for example cerebrovascular disease and heart failure, as well as the wider applications for lipid-lowering agents in the management of co-morbidities. The book concludes with a review of novel lipid-modifying agents, emerging diagnostic technologies such as intravascular ultrasound, and the use of biomarkers as risk predictors.

Benefits:
- Translates scientific evidence into improved clinical outcomes
- In-depth discussion of concomitant disorders associated with dyslipidaemia
- Synthesizing publication and trial data to enable effective diagnosis and targeted prescribing decisions

Readership:

- Cardiologists
- Endocrinologists
- Nephrologists
- General physicians
- Doctors in training

Editor and Contributors
Foreword

1 A global view of cardiovascular risk factors
C. K. Chow, A. A. Patel

2 Low-density lipoprotein cholesterol as a therapeutic target
J. Armitage, L. Bowman

3 High-density lipoprotein as a therapeutic target
P. Barter, K.-A. Rye

4 Apolipoprotein B in the therapy of atherogenic dyslipoproteinaemias
A. D. Sniderman

5 Management of coronary heart disease patients
K. K. Ray, C. P. Cannon

6 Stroke and transient ischaemic attack prevention
P. Amarenco, P. Lavallée, M. Mazighi, J. Labreuche

7 Diabetes and the metabolic syndrome
A. J. Cameron, J. Shaw, P. Zimmet

8 Hypertension
R. H. Grimm, Jr

9 Treatment of familial hypercholesterolaemia
R. Huijgen, H. J. Avis, B. A. Hutten, M. N. Vissers, J. J. P. Kastelein

10 Lipid lowering in chronic kidney disease
V. Perkovic, M. J. Jardine, M. Gallagher, A. Cass

11 Statins and heart failure
J. Kjekshus

12 Absolute risk assessment in the general population
L. Chen, A. M. Tonkin

13 Pleiotropic effects of statins and potential new indications
J. Davignon, H. Wassef

14 The role of imaging endpoints in clinical trials
S. J. Nicholls

15 Biomarkers in cardiovascular disease
S. Blankenberg, R. B. Schnabel

16 Novel lipid-modifying agents
E. A. Stein, K. M. Kostner, D. R. Sullivan

17 The enhanced evidence base and translation into improved outcomes
A. M. Tonkin

List of abbreviations
Index

Edited by:

- AM Tonkin, Cardiovascular Research Unit, Dept Epidemiology & Preventive Medicine, Monash University, Melbourne, Australia

Format Properties
E-Book (PDF) The electronic book will be shipped to you. The file format is PDF. This is a single user license, allowing one specific user access to the product.
Hard Copy (Hard Back) The book will be shipped to you. The cover has a hard back.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos